Pharmaceuticals News and Research

RSS

InnaVirVax announces Phase I/IIa clinical trial authorization for its VAC-3S HIV vaccine

InnaVirVax, a biopharmaceutical company dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation, declared today that it has obtained authorization from the French drug agency (AFSSAPS) to start a Phase I/IIa clinical study of its therapeutic vaccine VAC-3S for the treatment of HIV infections. This authorization intervenes only two years and half after the launching of InnaVirVax’s activities.

14 Oct 2011

Top-line results from POZEN's PA32540 Phase 3 trial on aspirin-associated gastric ulcers

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today top-line results from study 303, a Phase 3 trial designed to track the long-term safety of PA32540 in patients who are at risk for developing aspirin-associated gastric ulcers.

13 Oct 2011

AARP members take to the Hill to protect entitlements

In effort to reinforce national television advertising, more than 400 AARP volunteers and staffers will be on Capitol Hill today to remind lawmakers not to cut Medicare. Meanwhile, both Democratic and Republican leaders are sending clear messages to the "super committee" and their fellow lawmakers regarding what they think should be on the table and how to frame expectations.

13 Oct 2011

Mass. Medicaid waiver hits roadblock; N.Y. enrollment reaches 5 million

Politico reports that despite its health reform efforts, Massachusetts is having trouble getting the federal government to issue a waiver for Medicaid programs. The Wall Street Journal reports on the growing needs in New York.

13 Oct 2011

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."

13 Oct 2011

High dose vitamin E supplements may raise risk of prostate cancer: Study

The chances of developing the disease rose by 17 per cent, even years after men stopped taking the vitamin, claim researchers. This comes right after the study which found women taking multivitamins and other supplements have an increased risk of dying.

13 Oct 2011

Viewpoints: Screening for prostate cancer, stem cell research and free coverage for Iowa lawmakers

As a practicing internist, I need all the help I can get in diagnosing the many diseases that threaten the life and well-being of my patients. So perhaps you'll understand why I'm angered by the reckless new recommendations from the U.S. Preventive Services Task Force (a panel of primary care experts) that I don't use the prostate-specific antigen to screen men older than 40 for prostate cancer.

13 Oct 2011

Counterfeit drugs risk lives, threaten pharmaceutical industry in India

BBC News examines how counterfeit or substandard medicines are threatening India's fast-growing pharmaceutical industry, writing, "Worth over $12 billion, the industry is expected to grow more than four-fold in the coming decade," but fake drugs in the system are risking both the lives of patients and the reputation of drug makers.

12 Oct 2011

NCCN Oncology Research Program wins two GSK grants

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded $4 million in the form of two research grants from GlaxoSmithKline (GSK) to develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma.

12 Oct 2011

Idera announces new data on novel gene-silencing oligonucleotide technology

Idera Pharmaceuticals, Inc. today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the Cell Symposium on Regulatory RNAs in Chicago, IL.

12 Oct 2011

NIH, Genesis Biopharma enter Patent License Agreement for adoptive cell therapy

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, today announced it has entered into a Patent License Agreement with the National Institutes of Health, an agency of the United States Public Health Service within the Department of Health and Human Services

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

Bruker launches SHS-40 Automated Headspace Sampler

At the analytica AnaCon India conference in Mumbai, India, Bruker today announced the release of its newly developed SHS-40 Automated Headspace Sampler.

12 Oct 2011

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

12 Oct 2011

Study: Emerging pharmaceutical platform may produce undesirable effects on eye function

According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function.

12 Oct 2011

UB scientists discover promising new drug target for Alzheimer's

A tiny piece of a critical receptor that fuels the brain and without which sentient beings cannot live has been discovered by University at Buffalo scientists as a promising new drug target for Alzheimer's and other neurodegenerative diseases.

12 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011